The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer

Cell Biochemistry and Biophysics

Volumn 73, Issue 1, 2015, Pages 253-259

  Yan, Qin ^a   Yuan, Yin ^a   Yankui, Liu ^a   Jingjie, Feng ^a   Linfang, Jin ^a   Yong, Pu ^a   Dong, Hua ^a   Xiaowei, Qi ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; CXCR5; Matrix metalloproteinase 13; Metastasis; Prognosis

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; COLLAGENASE 3; CXCR5 PROTEIN, HUMAN; MMP13 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; INTESTINE MUCOSA; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, CXCR5;

EID: 84939266871     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-015-0624-6     Document Type: Article

References (13)

1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics. CA: A Cancer Journal for Clinicians,63(1), 11–30.
2. Markowitz, S. D., Dawson, D. M., Willis, J., & Willson, J. K. (2002). Focus on colon cancer. Cancer Cell,1(3), 233–236.
3. Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., Cervantes, A., & The ESMO Guidelines Working Group. (2010). Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Annals of Oncology,21(Suppl 5), v70–v77.
4. Franciszkiewicz, K., Boissonnas, A., Boutet, M., Combadière, C., & Mami-Chouaib, F. (2012). Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Research,72(24), 6325–6332.
5. Kataoka, H., Tanaka, H., Nagaike, K., Uchiyama, S., & Itoh, H. (2003). Role of cancer cell-stroma interaction in invasive growth of cancer cells. Human Cell,16(1), 1–14.
6. Bürkle, A., Niedermeier, M., Schmitt-Gräff, A., Wierda, W. G., Keating, M. J., & Burger, J. A. (2007). Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood,110(9), 3316–3325.
7. Freije, J. M., Diez-iltza, I., Balbin, M., et al. (1994). Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. Biological Chemistry,269, 16766–16773.
8. Mori, M., Barnard, G. F., Mimori, K., Ueo, H., Akiyoshi, T., & Sugimachi, K. (1995). Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer,75(6), 1516–1519.
9. Liotta, L. A., & Stetler-Stevenson, W. G. (1991). Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Research,51(18 Suppl), 5054s–5059s.
10. Van Nguyen, S., Skarstedt, M., Löfgren, S., Zar, N., Andersson, R. E., Lindh, M., et al. (2013). Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorectal cancer in Swedish patients. [J]. Anticancer Research,33(8), 3247–3250.
11. Razis, E., Kalogeras, K. T., Kotoula, V., Eleftheraki, A. G., Nikitas, N., Kronenwett, R., et al. (2012). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clinical Breast Cancer,12(3), 183–193.
12. Rath, T., Stöckle, J., Roderfeld, M., Tschuschner, A., Graf, J., & Roeb, E. (2011). Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncology Letters,2(3), 483–488.
13. Huang, M. Y., Chang, H. J., Chung, F. Y., Yang, M. J., Yang, Y. H., Wang, J. Y., & Lin, S. R. (2010). MMP13 is a potential prognostic marker for colorectal cancer. Oncology Reports,24(5), 1241–1247.